Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
3.370
-0.150 (-4.26%)
Official Closing Price
Updated: 4:00 PM EDT, May 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
22
23
Next >
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
↗
December 21, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
December 20, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
December 11, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
December 10, 2024
Via
Benzinga
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
↗
November 28, 2024
Via
Benzinga
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
↗
November 07, 2024
Via
Benzinga
Peering Into Recursion Pharmaceuticals's Recent Short Interest
↗
November 04, 2024
Via
Benzinga
What's Going On With Recursion Pharmaceuticals Stock?
↗
December 10, 2024
Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special...
Via
Benzinga
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
December 09, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
↗
December 06, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
December 04, 2024
Via
Benzinga
An Investor's Guide to the Artificial Intelligence (AI) Value Chain
↗
December 09, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
December 04, 2024
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Berkshire Hathaway Isn't the Only Publicly Traded Company That Buys Stocks. These 3 Tech Giants Also Have Stock Portfolios.
↗
December 04, 2024
Via
The Motley Fool
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
December 03, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
↗
December 02, 2024
Via
Benzinga
NVIDIA Invested in These 2 AI Stocks, Should You?
December 02, 2024
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.
Via
MarketBeat
Topics
Artificial Intelligence
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
↗
November 27, 2024
Jim Cramer praises Reddit, Inc. but warns of auto parts made in China. Recursion Pharmaceuticals and Dow Inc. face challenges. Super Micro Computer sells due to accounting irregularities.
Via
Benzinga
Topics
Stocks
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
↗
November 26, 2024
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Via
Benzinga
Topics
Artificial Intelligence
2 Innovative Stocks That Could Deliver Outsize Returns
↗
November 22, 2024
Via
The Motley Fool
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
November 20, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars
↗
November 15, 2024
Nvidia's purchase of 7.72 million shares of Applied Digital boosted the company's revenue and earnings. Applied Digital plans to expand its data centers and AI cloud infrastructure.
Via
Benzinga
Topics
Artificial Intelligence
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes
↗
November 15, 2024
Nvidia has disclosed an investment in Applied Digital, a digital infrastructure provider. Nvidia stock dipped while APLD stock rose.
Via
Investor's Business Daily
Recursion and Exscientia Shareholders Approve the Proposed Combination
November 13, 2024
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
November 12, 2024
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
↗
November 11, 2024
Via
Benzinga
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
10 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 04, 2024
Via
Benzinga
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
↗
November 02, 2024
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
Via
The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
↗
October 31, 2024
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.